FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to neurology pharmaceutical companies.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Dementia with Lewy Bodies
- Sub-indication
- General
Related signal: Red-light therapy trial for Dementia with Lewy Bodies shows potential for cognitive and quality of life improvements